Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold, MB; Khanna, D; Denton, CP; van Laar, JM; Frech, TM; Anderson, ME; Baron, M; ... Pope, JE; + view all Arnold, MB; Khanna, D; Denton, CP; van Laar, JM; Frech, TM; Anderson, ME; Baron, M; Chung, L; Fierlbeck, G; Lakshminarayanan, S; Allanore, Y; Riemekasten, G; Steen, V; Müller-Ladner, U; Spotswood, H; Burke, L; Siegel, J; Jahreis, A; Furst, DE; Pope, JE; - view fewer (2017) Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology 10.1093/rheumatology/kex396 . (In press).

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2hGLix7
via IFTTT